For this reason, innovative BCR-ABL targeted or NON BCR-ABL targeted drugs can be considered as a valid alternative for CML patients resistant/intolerant to conventional treatment. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.